Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive

ADVERTISEMENT

Deals
Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

GSK to Pay $1 Billion for Synta Melanoma Drug

October 17, 2007

In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug.

M&A: Panning for Gold

September 1, 2007

here's a solid case to be made for choosing A. The market for deals has been robust through the first half of 2007. A Cowen research report counted 10 public deals done by July 2007, compared with 14 for all of 2006. Another data source, Irving Levin Associates, cites 455 public and private healthcare deals in the first six months of 2007, a 12 percent decrease from the same period last year—but an 18 percent rise in deal value.

Novartis to Intercell: "Gimme All Your Vax."

July 11, 2007

But is the pharma-biotech vaccine deal a prelude to a takeover?

Roche to Ventana: "Let's Make A Deal"

July 11, 2007

...And the spurned suitor won't take "No" for an answer

Actavis Going Private?

July 3, 2007

The month in deals: Merck KGaA's generics unit goes to Mylan; Genzyme acquires its partner in a key oncology drug; and Amgen makes significant acquisitions in kidney disease and diabetes/inflammatory diseases

A Very Specialty Moment

June 1, 2007

While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.

Biotech, The Incredible Swelling Industry

May 2, 2007

New report names 2006 'year of the deal.'

AstraZeneca Serious, 'Not Desperate,' in MedImmune Deal

May 2, 2007

Pricey merger adds expertise in vaccines, biologics.

Spend Trends 2007: Hang 10

May 1, 2007

Direct-to-consumer advertising officially becomes a "tweenager" this August—and, oh my, how it has grown. DTC was officially born in 1997 when FDA gave the green light to companies to advertise their drugs to consumers. In the first year, pharmaceutical marketers bounded onto the scene and spent more than $1 billion. Years passed. Debates ensued. Patients learned more about drugs. And, yes, spending grew. The latest available figures for 2006 show that the industry spent $4.8 billion on DTC advertising, a 13 percent increase over 2005 and the second year of double-digit growth.

ADVERTISEMENT

Click here